RPG Life Sciences Limited, a leading name in pharmaceutical products manufacturing and marketing, has unveiled its financial results for Q2 FY24. The company’s revenue from operations for this quarter was an impressive Rs 153.58 crores, marking a significant rise from Rs 134.79 crores of the previous year. Additionally, its profit before tax (PBT) for the same period reached Rs 34.79 crores, up from Rs 27.01 crores, indicating strong financial performance.

RPG Life Sciences H1 FY24 Financial Highlights

For the first half of FY24, RPG Life Sciences continued its stellar financial journey. The company’s half-yearly revenue from operations clocked in at Rs 301.36 crores, a notable increase from the previous year’s Rs 263.72 crores. The PBT for H1 FY24 stood at Rs 64.56 crores, ascending from Rs 52.13 crores of the preceding year.

Stellar Performance & Growth Trajectory

For Q2 FY24, RPG Life Sciences reported a commendable 29% Y-o-Y growth in PBT and 17% Q-o-Q growth. This was complemented by an upward trend in EBITDA margins, which augmented from 23.0% to 25.5% both Y-o-Y and Q-o-Q. Similarly, the company’s H1 FY24 results saw a 29% Y-o-Y surge in PBT, with EBITDA margins escalating from 22.8% to 24.3% Y-o-Y.

Yugal Sikri, Managing Director of RPG Life Sciences Ltd., commented on the performance, stating, “In Q2 FY24, the company’s overall performance remained robust with a 14% growth in Revenue and a 29% increase in PBT Y-o-Y. EBITDA margins have consistently grown over the past five years, going from 23.0% to 25.5% Y-o-Y. Notably, the company stands debt-free.

“The Domestic Formulations business, our primary revenue contributor, has seen vigorous growth. Simultaneously, the International Formulations business has emerged as another significant growth factor, showcasing healthy growth in sales and profits. We’re making strategic investments in modernizing plants and expanding capacities. Our focus on cost efficiencies and sales hygiene is paving the way for improved margins, aligning with our transformation agenda and strategic goals.”

  India, RPG Life Sciences